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Background: High levels of circulating fibroblast growth factor 23 (FGF23) are associated with chronic kidney
disease (CKD) progression and high mortality. In the Phosphate Reduction Evaluation of FGF23 in Early CKD
Treatment (PREFECT) study, we assessed the effect of reducing intestinal phosphate absorption using lanthanum
carbonate on FGF23 levels in normophosphatemic patients with CKD stage 3.
Methods: Thirty-five individuals were randomized to lanthanum carbonate 3000 mg/day (n = 23) or placebo
(n = 12) for 12 weeks. Levels of intact FGF23 (iFGF23), C-terminal FGF23, serum and urinary phosphate and calcium,
intact parathyroid hormone and 1,25-dihydroxyvitamin D were assessed.
Results: The median age was 65 years in the lanthanum group and 73 years in the placebo group; 58.8% and
41.7% were men, respectively. No significant difference was seen in mean iFGF23 between groups at week 12.
There was, however, a transient reduction from baseline in iFGF23 in the lanthanum group at week 1, from
70.5 pg/ml to 51.9 pg/ml, which was not seen in the placebo group; this between-group difference in percentage
change from baseline was significant in post hoc analyses (p = 0.0102). Urinary phosphate decreased after 1 week of
lanthanum treatment and remained low at week 12.
Conclusions: Reducing intestinal phosphate absorption with lanthanum carbonate did not lead to sustained
reductions in iFGF23 in patients with CKD stage 3, although phosphaturia decreased. This suggests that factors
other than phosphate burden may be responsible for driving increases in circulating FGF23 in patients with CKD.
Trial registration: ClinicalTrials.gov NCT01128179, 20 May 2010.
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Fibroblast growth factor 23 (FGF23) plays a central role in
mineral and bone disorders associated with chronic kid-
ney disease (CKD-MBD) [1]. FGF23 levels are elevated
early in CKD and increase as the disease progresses [2].
Increased circulating FGF23 levels are associated with an
increased risk of peripheral vascular calcification [3], heart
disease [4-9] and death [10-12]. In animal models, FGF23
can directly induce left ventricular hypertrophy, which can
be prevented by blocking the intracellular signaling
pathway stimulated by FGF23 [13]. It is not clear, how-
ever, whether increased circulating FGF23 levels in pa-
tients with CKD are causative of cardiovascular disease,
or whether FGF23 is simply a biomarker for CKD-MBD
severity [14].
The increase in FGF23 levels with progressing CKD
probably occurs as part of the skeletal response to in-
creased phosphate burden that results from a reduced
number of functional nephrons [15]. In support of this,
two studies have shown an association between increased
dietary phosphate intake and serum FGF23 levels [5,16].
In a separate study, however, modest increases (33%) in
dietary phosphate were not associated with increased
FGF23 levels [17].
Reducing circulating FGF23 levels is a therapeutic goal
for CKD-MBD, and strategies for achieving this have
involved decreasing the phosphate load [18-20]. For in-
stance, in one study of patients with CKD, a very-low-
protein diet containing 0.3 g protein/kg of body weight/
day (< 500 mg/day of phosphate) led to a significant de-
crease in FGF23 levels [21]; however, submitting individ-
uals with CKD to such a protein-restricted diet exposes
them to a high risk of malnutrition [22]. Thus, maintain-
ing an appropriate protein and caloric intake in patients
with CKD indisputably requires the decrease of intes-
tinal absorption of phosphate [22,23].
Results of previous studies are conflicting, showing that
treatment with intestinal phosphate binders can lead to no
evidence of change, reductions or increases in FGF23
levels [18,19,24]. The primary objective of the PREFECT
study was to assess the effects of 12 weeks of treatment
with lanthanum carbonate compared with placebo on in-
tact FGF23 (iFGF23) levels in normophosphatemic pa-
tients with CKD stage 3.
Secondary and tertiary objectives were to assess the ef-
fects of lanthanum carbonate on other factors that are
altered in CKD-MBD, including circulating levels of in-
tact parathyroid hormone (iPTH), 1,25-dihydroxyvitamin
D, calcium, and phosphate.
Methods
Study population
Men and non-pregnant, non-lactating women aged 18 years
or over with CKD stage 3 were included in the study.Patients had to have been under the care of a physician for
at least 2 months, and not be expected to begin dialysis
for at least 6 months. At screening, patients had to have
serum phosphate levels within the normal range (0.808–
1.55 mmol/l), an estimated glomerular filtration rate
(eGFR) (estimated using the Cockcroft–Gault and Modifi-
cation of Diet in Renal Disease [MDRD] formulae [25]) of
30–59 ml/min/1.73 m2, C-terminal FGF23 (cFGF23)
levels ≥ 50.0 RU/ml and 25-hydroxyvitamin D levels ≥
20 ng/ml. Patients also had to have an adequate protein
diet that included two or three portions of protein-rich
food per day, as determined at screening. Those who re-
quired vitamin D supplements or compounds containing
calcium, phosphate, aluminum or magnesium were ex-
cluded. Individuals were also excluded if they had: acute
kidney failure; rapidly progressing glomerulonephritis; cir-
rhosis or other clinically significant liver disease; human
immunodeficiency virus infection; life-threatening malig-
nancy or multiple myeloma; or any clinically significant ill-
ness that would, in the opinion of the investigator, impair
their ability to give informed consent or to take part in or
complete the study. Patients with a history of gastrointes-
tinal disorders, alcohol or substance abuse, or poor compli-
ance (< 60% or > 120% tablets taken) were excluded, as
were vegetarians and patients allergic to iodine.
Patients were withdrawn from the study if: their serum
phosphate concentration fell below 0.60 mmol/l; their
medical condition deteriorated significantly in the opin-
ion of the investigator; they had a major change in diet;
they commenced dialysis or required a kidney trans-
plant; they had unmanageable adverse events; or if they
became pregnant.
The study was conducted in accordance with all applic-
able regulations, the International Conference on Har-
monisation guideline for Good Clinical Practice [26], and
the Declaration of Helsinki and its subsequent revisions
[27]. The study protocol and informed consent documents
received ethical approval from the institutional ethical re-
view committee: Comité de Protection des Personnes, Ile
de France II. Necker Hospital, Paris, France. All patients
provided written informed consent before participating in
the study.
Study design
This was a phase 2a, double-blind, placebo-controlled,
proof-of-concept study carried out between November
2010 and May 2012 (ClinicalTrials.gov identifier:
NCT01128179). Participants were screened within a 2-
week period, then returned for a baseline visit at which
their eligibility for inclusion in the study was confirmed
before they were randomized, by sequential allocation of a
unique 2-digit number by the investigator that matched
a 2-digit number on the study medication. Treatment
was assigned by a randomization schedule and patients
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Shire, Nyon, Switzerland) 1000 mg three times daily, or
a placebo equivalent for 12 weeks (Figure 1A), details of
which were in the form of code-break envelopes held at
the investigational site. The investigational product was
to be chewed rather than swallowed whole, and was rec-
ommended to be taken with meals. Patients returned to
the clinic site for visits 1, 2, 8 and 12 weeks after the
baseline visit, and a follow-up call was scheduled for
week 16, or 30 days after the end of treatment if the in-
vestigational product was discontinued before study
completion.
The primary endpoint was iFGF23 level at week 12.
Secondary endpoints were: iPTH, 1,25-dihydroxyvitamin
D, phosphate, total calcium and calcium × phosphate
product; 24-h urinary phosphate and calcium excretion;
urinary creatinine and urea nitrogen concentrations.
Tertiary endpoints were: 25-hydroxyvitamin D, ionized
calcium, creatinine and cFGF23; GFR as measured by
plasma iohexol clearance (iGFR) according to previously
described methods [28], and eGFR; CrossLapsW (a meas-
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Figure 1 (A) Study design and (B) population. Schedule of assessments
bone-specific ALP, iPTH; b = eGFR; c = 24-h urinary phosphate, calcium crea
e = adverse events. ALP, alkaline phosphatase; cFGF23, C-terminal fibroblast
intact fibroblast growth factor 23; iGFR, iohexol glomerular filtration rate; iPBlood samples were collected at screening and all subse-
quent visits for measurement of iFGF23, cFGF23, 25-
hydroxyvitamin D, 1,25-dihydroxyvitamin D, bone-specific
alkaline phosphatase and iPTH levels. Twenty-four-hour
urine samples were collected at all visits from baseline to
week 12 for assessment of phosphate, calcium, creatinine
and urea nitrogen levels. One day prior to the visit, each
patient was asked to discard their first morning urination,
to note the time on the urinary bottle, and then to collect
the urine of all subsequent micturitions for 24 h. The time
of the last urination was also noted on the bottle. eGFR
was assessed at screening, baseline and week 12. iGFR,
ionized calcium and CrossLaps® were assessed at baseline
and week 12. Vital signs and adverse events were moni-
tored at every visit from screening to the final visit. Ad-
verse events were also recorded on the follow-up call.
Compliance was calculated based on the number of tab-
lets remaining in medicine bottles returned at the end of
the study.
The study was conducted at a single center (Service de
Néphrologie-Dialyse, Clinique du Landy, Paris, France),
and measurement of GFR and biochemical evaluations
were performed at a single department (Service deued n = 2
l violation  (eGFR < 30 ml/min/1.73 m2) n = 1
 = 1
 n = 4
ance < 60% n = 2
ted medication (calcium-containing compound) n = 1








: a = iFGF23, cFGF23, 25-hydroxyvitamin D, 1–25 dihydroxyvitamin D,
tinine and urea nitrogen; d = iGFR, ionized calcium, CrossLaps®;
growth factor 23; eGFR, estimated glomerular filtration rate; iFGF23,
TH, intact parathyroid hormone.
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Enfants Malades, Paris, France).
Statistical analyses
Previous work by one of the authors (DP) showed fasting
FGF23 levels in patients with CKD to be log-normally dis-
tributed with a coefficient of variation of the logged data of
1.13 (author’s unpublished data). A sample size of 33 par-
ticipants randomized in a 2:1 ratio (22 receiving lanthanum
carbonate and 11 receiving placebo) was estimated to be
sufficient to detect a ratio of 1.15 in the logged means, or a
40% reduction in mean iFGF23 levels in the lanthanum
carbonate group compared with the placebo group at
12 weeks. This assumed 80% power and a two-sided sig-
nificance level of 5%.
Patients who were randomized and received at least
one dose of the investigational product were included in
the safety analysis set. Patients in the safety analysis set
who had at least one post-dose assessment were included
in the full analysis set. The per protocol set consisted of
patients who had at least one dose of investigational prod-
uct in addition to primary data assessment available from
week 2 or later, and who did not have any pre-defined
protocol deviations that might affect the primary variable.
The per protocol set was the primary analysis population
for this proof-of-concept study.
Data were presented as descriptive statistics, which are
shown as mean ± standard deviation (SD) or percentage
change from baseline in the least-squares (LS) mean ±
standard error. Statistical analyses were performed using
SASW version 9.1 (SAS Institute, Cary, NC, USA). Differ-
ences in the primary endpoint, iFGF23 levels, between
the placebo and lanthanum carbonate groups at week 12
were evaluated using analysis of covariance (ANCOVA)
and log-transformed values, with baseline iFGF23 as a co-
variate. ANCOVA models were also used to evaluate the
statistical significance of differences in secondary and ter-
tiary variables using change from baseline to week 12, with
treatment group as a factor and the corresponding value
at baseline as a covariate. Missing data were accounted for
using the last observation carried forward method. In post
hoc analyses, ANCOVA was used to evaluate the statistical
difference in the percentage change from baseline in the




In total, 51 patients were screened, of whom 35 met the
inclusion criteria and entered the study. These individ-
uals made up the safety analysis set and were random-
ized such that 23 patients received lanthanum carbonate
and 12 received placebo (Figure 1B). All patients included
in the safety analysis set also made up the full analysis set.In the lanthanum carbonate group, two participants did
not complete the study: one died (not considered to be
treatment related); the other was withdrawn because of a
protocol violation (eGFR < 30 ml/min/1.73 m2). Also in
the lanthanum carbonate group, four patients completed
the study but met exclusion criteria and were not included
in the per protocol analysis set.
Baseline characteristics of the per protocol analysis set
were similar to the safety analysis set (Table 1); however,
there were some numerical differences between the lan-
thanum carbonate and placebo groups. The median age
was 65 years (range: 38–84 years) in the lanthanum car-
bonate group and 73 years (range: 43–87 years) in the
placebo group. In the lanthanum carbonate group, 58.8%
of patients were men, compared with 41.7% of those in
the placebo group. Most participants were white (lan-
thanum carbonate group: 70.6%; placebo group: 75.0%),
and there was a higher proportion of black patients in
the lanthanum carbonate group (29.4%) than in the pla-
cebo group (16.7%). Individuals in the lanthanum carbon-
ate group had a lower iGFR (mean: 42.2 ml/min/1.73 m2,
standard deviation [SD]: 10.1 ml/min/1.73 m2) than the
placebo group (mean: 48.0 ml/min/1.73 m2, SD: 13.1 ml/
min/1.73 m2) at baseline. Mean treatment compliance,
measured by the proportion of tablets left in the medicine
bottle at the treatment visit, was 87.5% (SD: 20.1%) in the
lanthanum carbonate group and 91.0% (SD: 13.0%) in the
placebo group.
iFGF23 and cFGF23 levels
Numerical changes in mean iFGF23 levels were seen
between the lanthanum carbonate and placebo groups
throughout the treatment period, although there was no
statistically significant difference in the per protocol set
between the groups at week 12, the primary endpoint of
the study (p = 0.3186 from F-test of logged LS mean
iFGF23 values) (Figure 2A). This was also true of the
safety/full analysis set, in which there was no statisti-
cally significant difference in LS mean iFGF23 at week
12 (p = 0.6330). Across all the analyses, the results were
similar for the per protocol set and the safety analysis
set, and these groups had similar baseline characteris-
tics; therefore, only efficacy results for the per protocol
analysis set are presented.
In the lanthanum carbonate group, mean iFGF23 levels
decreased from 70.5 pg/ml (SD: 32.2 pg/ml) at baseline to
51.9 pg/ml (SD: 18.2 pg/ml) at week 1; however, they sub-
sequently increased to 58.8 pg/ml (SD: 20.6 pg/ml) by
week 12. For patients given placebo, there was negligible
change in mean iFGF23 levels throughout the study (base-
line: 63.7 pg/ml (SD: 14.8 pg/ml); week 12: 63.7 pg/ml
(SD: 21.7 pg/ml).
The percentage change from baseline in LS mean
iFGF23 levels was also retrospectively assessed for each
Table 1 Patient demographics at baseline (week 0, safety
analysis set and per protocol analysis set)






(n = 23) (n = 12) (n = 17) (n = 12)
Age, years
Mean (SD) 66.0 (13.9) 69.4 (13.2) 65.6 (14.7) 69.4 (13.2)
Median 65.0 72.5 65 73
Range 38–84 43–87 38–84 43–87
Gender, n (%)
Male 13 (56.5) 5 (41.7) 10 (58.8) 5 (41.7)
Ethnicity, n (%)
White 16 (69.6) 9 (75) 12 (70.6) 9 (75.0)
Black 6 (26.1) 2 (16.7) 5 (29.4) 2 (16.7)
Asian 0 (0.0) 1 (8.3) 0 (0.0) 1 (8.3)
Body mass index,
kg/m2, mean (SD)
29.9 (5.1) 30.1 (5.1) 29.4 (4.9) 30.1 (5.1)
iGFR (ml/min/
1.73 m2), mean (SD)
42.5 (10.7) 48.0 (13.1) 42.2 (10.1) 48.0 (13.1)















































Figure 2 iFGF23 and cFGF23 levels over time. (A) Mean iFGF23 levels, (
(C) mean cFGF23 levels and (D) LS mean percentage change from baseline
significance was assessed using analysis of covariance. Lanthanum carbona
missing from the placebo group at week 1. (A) and (C) show mean values
cFGF23, C-terminal fibroblast growth factor 23; iFGF23, intact fibroblast gro
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reduction in iFGF23 in the lanthanum carbonate group
compared with the placebo group was statistically signifi-
cant at week 1 (p = 0.0102); however, a statistically signifi-
cant difference was not seen at subsequent time points.
Mean FGF23 levels were also assessed using an assay
to detect the tertiary variable, cFGF23 (Figure 2C). Post
hoc analysis showed that there was a reduction at all
weeks in the percentage change from baseline in LS
mean cFGF23 levels in the lanthanum carbonate group,
whereas these levels increased or were slightly reduced
(week 8) in the placebo group (Figure 2D). The between-
group difference was significant 2 and 8 weeks after the
start of treatment (p < 0.05, ANCOVA), but not after 1 or
12 weeks.
Serum and urinary phosphate and calcium levels
Secondary variables, serum and urinary phosphate and cal-
cium levels were assessed during the study and between-
group differences were analyzed statistically at week 12
(Figure 3; Additional file 1: Table S1). Serum phosphate
was lower in the lanthanum carbonate group than in the
placebo group throughout the study, including the baseline
visit, but there was no significant difference in serum
phosphate between groups after 12 weeks (Figure 3A).
Twenty-four-hour urinary phosphate excretion was gener-





















































































B) LS mean percentage change from baseline in iFGF23 levels,
in cFGF23 levels. *p = 0.0102; **p < 0.05 vs placebo. Statistical
te, n = 17; placebo n = 12. For cFGF23 (c and d) one patient was
± standard deviation; (B) and (D) show LS mean ± standard error.



































































































































































































































































Figure 3 Changes in phosphate and calcium levels throughout the study. (A) Serum phosphate, (B) 24-h urinary phosphate excretion, (C)
serum total calcium, (D) serum calcium × phosphate product, (E) 24-h urinary calcium excretion and (F) estimated daily dietary phosphate intake.
Graphs show mean values ± standard deviation. LC, lanthanum carbonate; PBO, placebo.
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week 12 (p = 0.0162) (Figure 3B, Additional file 1: Table
S1). In the lanthanum carbonate group, phosphate excre-
tion decreased from 18.2 mmol/24 h (SD: 6.8 mmol/24 h)
at baseline to 14.4 mmol/24 h (SD: 7.9 mmol/24 h) at
week 2 and remained at this level until week 12
(14.5 mmol/24 h [SD: 6.4 mmol/24 h]). Phosphate excre-
tion in the placebo group increased from a mean of
16.2 mmol/24 h (SD: 9.1 mmol/24 h) at baseline to
22.5 mmol/24 h (SD: 10.9 mmol/24 h) by week 12.
Serum total calcium level and calcium × phosphate
product were similar in the placebo and lanthanum car-
bonate groups, and remained constant throughout thestudy (Figure 3C and 3D). Urinary calcium levels were
generally higher in the lanthanum carbonate group than
in the placebo group (Figure 3E); however, by week 12,
urinary calcium levels had increased in the placebo
group (2.72 mmol/24 h [SD: 1.12 mmol/24 h]) and had
fallen to below placebo levels in the lanthanum carbonate
group (1.78 mmol/24 h [SD: 0.90 mmol/24 h]). There was
a significant difference between the decrease in urinary
calcium from baseline in the lanthanum carbonate group
and the increase from baseline in the placebo group at
week 12 (p = 0.0371; Additional file 1: Table S1).
Daily dietary phosphate intake was not measured dir-
ectly in this study, but was estimated retrospectively using







n (%) Events n (%) Events
Any adverse event 7 (30.4) 15 2 (16.7) 3
Related to investigational
product
2 (8.7) 6 1 (8.3) 1
Moderate or severe adverse event 2 (8.7) 4 – – –
Serious adverse event 2 (8.7) 4 – – –
Related to investigational
product
– – – – – –
Leading to withdrawal of
investigational product
1 (4.3) 1 – – –
Type of adverse event
Gastrointestinal disorders 4 (17.4) 4 2 (16.7) 3
Abdominal discomfort – – – 1 (8.3) 1
Constipation 2 (8.7) 2 – – –
Diarrhea – – – 1 (8.3) 1
Dry mouth 1 (4.3) 1 – – –
Acute pancreatitis 1 (4.3) 1 – – –
Vomiting – – – 1 (8.3) 1
Cardiac disorders 1 (4.3) 3 – – –
Cardiac failure 1 (4.3) 2 – – –
Myocardial infarction 1 (4.3) 1 – – –
Other organ system classes
Thirst 1 (4.3) 1 – – –
Bronchitis 1 (4.3) 1 – – –
Anorexia 1 (4.3) 1 – – –
Headache 1 (4.3) 1 – – –
Polyuria 1 (4.3) 1 – – –
Erythema 1 (4.3) 1 – – –
Hyperhidrosis 1 (4.3) 1 – – –
Hypertension 1 (4.3) 1 – – –
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phosphate intake was similar both between the two
treatment groups, and within each group throughout
the study (Figure 3F).
Intact parathyroid hormone and 1,25-dihydroxyvitamin
D levels
Mean iPTH and 1,25-dihydroxyvitamin D levels for each
treatment group were measured as secondary variables
throughout the study (Additional file 2: Figure S1). Mean
iPTH levels were similar in the placebo and lanthanum
carbonate groups: there was a decrease from baseline
(placebo: 75.8 pg/ml [SD: 43.9 pg/ml], lanthanum car-
bonate: 69.4 pg/ml [SD: 30.4 pg/ml]) to week 1 (placebo:
62.2 pg/ml [SD: 38.1 pg/ml], lanthanum carbonate:
51.6 pg/ml [SD: 22.2 pg/ml]) in both groups, but levels
returned to close to baseline values by week 12. In patients
who received placebo, there was a small numerical de-
crease in mean 1,25-dihydroxyvitamin D levels by week 12
compared with baseline (−9.5 pg/ml [SD: 19.6]), whereas
there was no change from baseline to week 12 in the lan-
thanum carbonate group (0.1 pg/ml [SD: 12.2 pg/ml]). No
significant difference in the change from baseline was seen
between the LS means of the lanthanum carbonate and
placebo groups for iPTH (p = 0.2995) or for 1,25-dihydrox-
yvitamin D (p = 0.3252; Additional file 1: Table S1).
Serum or urinary levels of other relevant variables (urin-
ary fractional phosphate excretion, creatinine, urea nitro-
gen, 25-hydroxyvitamin D, ionized calcium, CrossLaps®,
iGFR and bone-specific alkaline phosphatase) are shown
in Additional file 1: Table S1. No significant between-
group differences were seen between weeks 0 and 12 for
these factors.
Post hoc subgroup analysis of iFGF23 levels
Retrospective subgroup analyses were undertaken to as-
sess whether baseline differences between the lanthanum
carbonate and placebo groups affected circulating iFGF23
levels over time (Additional file 3: Figure S2). Patients with
baseline eGFR below 45 ml/min (CKD stage 3b) showed
greater reductions in iFGF23 in both the lanthanum
carbonate and placebo groups, than individuals with a
baseline eGFR in the range 45–60 ml/min; however, no
significant difference was seen between placebo and
lanthanum carbonate treatment in either eGFR group.
Covariate analyses found no association of the percent-
age change from baseline of iFGF23 at any time point
with baseline cFGF23, baseline iPTH, estimated daily
phosphate intake or patient gender.
Safety evaluation
A summary of adverse events experienced in the study is
given in Table 2. In total, 30.4% of patients experienced ad-
verse events in the lanthanum carbonate group comparedwith 16.7% in the placebo group. The most frequently
observed adverse events were gastrointestinal (17.4% for
lanthanum carbonate vs 16.7% for placebo), including con-
stipation, dry mouth and acute pancreatitis. Two patients
(8.7%) treated with lanthanum carbonate experienced ser-
ious adverse events but neither event was considered to be
related to the investigational product: one patient experi-
enced acute pancreatitis; the other died following cardiac
failure and myocardial ischemia.
Discussion
In this study, the effect of lanthanum carbonate on cir-
culating FGF23 levels and other biochemical markers of
CKD-MBD was observed over a 12-week period. The
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statistically significant difference was seen in circulating
iFGF23 levels between patients treated with placebo and
those receiving lanthanum carbonate after 12 weeks of
treatment.
It was expected that lanthanum carbonate treatment
would reduce phosphate load, observed as reductions in
serum phosphate concentration and urinary phosphate
excretion, and subsequently that circulating FGF23 levels
would be reduced. This hypothesis was supported by a
previous study of 18 patients with CKD stage 3, which
showed that FGF23 levels were significantly reduced after
4 weeks of treatment with lanthanum carbonate 2250 mg/
day, and that urinary phosphate excretion was reduced ac-
cordingly [19]. In the present study in normophosphate-
mic individuals with CKD, however, the trend in urinary
phosphate levels did not correspond to that of either cir-
culating iFGF23 or cFGF23 levels. Notably, after an initial
reduction in urinary phosphate excretion following drug
administration, urinary phosphate levels tended to remain
constant in the lanthanum carbonate group, whereas cir-
culating iFGF23 levels started to rise again from week 2.
Although a correlation between these factors was not
specifically assessed, the differing trends between urin-
ary phosphate excretion and circulating iFGF23 suggest
that phosphate burden may not be the main factor driv-
ing the increase in FGF23 levels seen in CKD-MBD.Table 3 Comparison of published studies that assess the effe
Reference Intervention iFGF23/cFGF23 N CKD
Isakova et al.,
CJASN [20]
Placebo; LC; P-restricted diet +
placebo; P-restricted diet + LC
cFGF23 only 39 3–4
Yilmaz et al.,
AJKD [32]








LC; Placebo (both on
P-controlled diet either










et al., NDT [19]
LC cFGF23 18 3
LC: lanthanum carbonate, P: phosphate, FGF23: fibroblast growth factor 23; iFGF23:This supports the suggestion that FGF23 could be a
useful biomarker for detecting CKD-MBD progression
in advance of observed changes in serum phosphate
levels [29].
One possibility is that reductions in intestinal phos-
phate absorption and in extracellular phosphate burden
in the first 2 weeks of treatment in the present study re-
sulted in reduced FGF23, but that underlying bone dis-
ease and altered osteocyte/osteoblast/osteoclast function
or a compensatory mechanism drove increases in FGF23
production or decreases in FGF23 degradation after this
time. This is consistent with an idea recently put forward
that there are two distinct components of the FGF23
regulatory mechanism: one that is affected by changes in
circulating phosphate concentrations, and another that is
linked to the progression of CKD [20].
Although covariate analyses showed no statistically
significant influence of baseline parameters on iFGF23
levels between the treatment groups at baseline, there
were some potentially clinically significant differences
between the groups. First, whereas patients in the pla-
cebo group had GFR levels corresponding to CKD stage
3a, the lanthanum carbonate group had CKD stage 3b.
Secondly, more men and more black patients were in-
cluded in the lanthanum carbonate group than in the
placebo group; both race and gender have been reported
to have a potential influence on circulating FGF23 levelsct of phosphate binders on FGF23
stage Duration Results
12 weeks Significant 35% reduction in FGF23 in the
P-restricted + LC group at week 12 vs baseline.
No significant change in FGF23 from baseline
in other groups.
8 weeks Sevelamer group: reduction (27.1%) at week 8.
Calcium acetate group: increase (3.5%) at
week 8. Significance of changes from baseline
not specified.
6 weeks For patients with stage 3 CKD:
• Sevelamer group: significant reduction in FGF23
at week 6 (34.6%).
• Calcium group: non-significant reduction in
FGF23 at week 6 (24.7%).
2 weeks No significant change from baseline.
Slight increase from baseline in the group
ingesting 1500 mg P + placebo.
9 months No significant differences in cFGF23.
Change from baseline of iFGF23:
• Sevelamer: small but significant reduction.
• Calcium acetate: small but significant increase.
• LC and Placebo: no change.
4 weeks Significant reduction (21.8%) from baseline
of cFGF23.
intact FGF23; cFGF23: carboxy-terminal FGF23.
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other as yet unidentified factors that contribute to
FGF23 regulation.
The effect of lanthanum carbonate treatment on circulat-
ing FGF23 levels in patients with CKD has been reported
in several previous studies (Table 3). Gonzalez-Parra et al.
demonstrated a decrease in FGF23 in patients with CKD
stage 3 after 4 weeks of treatment with lanthanum carbon-
ate [19]. Isakova et al. saw a reduction in FGF23 values
after 12 weeks of treatment with lanthanum carbonate in
patients with CKD stages 3 or 4, but only if administered
in combination with a phosphate-restricted diet [20]. Other
studies on lanthanum carbonate in patients with CKD
stages 3–4 have shown no significant change in circulating
FGF23 levels using cFGF23 or iFGF23 after 2 weeks [24]
or 9 months [31]. FGF23 has also been assessed follow-
ing treatment with sevelamer or calcium-based phos-
phate binders [18,31,32]. Sevelamer treatment led to a
reduction in circulating FGF23 levels in patients with
CKD stages 3–4 after 6 weeks [18], and 9 months of
treatment [31], and after 8 weeks in patients with CKD
stage 4 [32]. There was a less consistent effect of calcium-
based phosphate binders on FGF23 in these studies. The
inconsistent results between these publications suggest
that further studies are required, using a larger sample size
and controlled dietary phosphate, to clearly determine
whether there is any differing effect between intestinal
phosphate binder types and FGF23. Notably, the exact
stage of CKD varies between the studies discussed here
and this may have a substantial effect on the FGF23
response.
One of the strengths of the present work is that the pa-
tient population had a measured GFR that allowed CKD
stage 3 to be very well defined. A limitation of the present
study was the small number of patients recruited, which
could be responsible for the high within-group variability,
and the lack of significance in statistical tests. The calcula-
tions used to determine the study sample size were pow-
ered to detect a 40% decrease in FGF23, whereas the
greatest reduction in FGF23 that was observed was 20%: a
larger sample size would be needed to detect statistically
significant differences between the groups based on this
effect size. A second limitation was that the completeness
of 24 h urinary samples was not assessed, although urinary
creatinine was assessed. Thirdly, dietary phosphate was
not controlled throughout the study. Patients were en-
couraged not to alter their eating habits during the study
and protein intake was retrospectively estimated based on
urea nitrogen levels; however, non-protein sources of
phosphate would not necessarily be identified using this
method. This limitation is particularly important in light
of a recent paper that saw an effect of lanthanum carbon-
ate on circulating FGF23 levels only in combination with
a phosphate-restrictive diet [20].Conclusions
Circulating iFGF23 levels were not significantly reduced
in patients with CKD stage 3 after 12 weeks of treatment
with lanthanum carbonate compared with placebo, despite
a reduction in urinary phosphate excretion and a transient
reduction in iFGF23 at week 1. This suggests that phos-
phate burden may not be the main driver of the increase
in circulating FGF23. Further studies with a larger sam-
ple size are required to confirm whether reducing intes-
tinal phosphate absorption by phosphate binders is
sufficient to bring about long-term reductions in circu-
lating FGF23 levels.
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